DiaMedica Therapeutics Inc
NASDAQ:DMAC
DiaMedica Therapeutics Inc
NASDAQ:DMAC
Price:
2.6 USD
2.77%
Market Closed
Updated:
May 1, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of DMAC.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
DMAC
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
DMAC Competitors Multiples
DiaMedica Therapeutics Inc Competitors
DiaMedica Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
98.7m USD | 0 | -5.1 | -2.2 | -2.2 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
288.7B USD | 5.3 | 59.9 | 13 | 19.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
147.9B USD | 5.2 | 22 | 16.4 | 24.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103B USD | 10.4 | 28.5 | 22.8 | 23.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.5B USD | 7.5 | 24.9 | 16.5 | 18.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132.6B AUD | 6.1 | 34.7 | 21.1 | 26.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 14.4 | 7.9 | 10.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
41.7B USD | 6.1 | -8.8 | -9.3 | -7.9 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | 27 | 14.6 | 18.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
